Introduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle Disease Virus.

Haas, C; Ertel, C; Gerhards, Roswitha; Schirrmacher, Volker

doi:10.3892/ijo.13.6.1105

Cited by 26 publications

(18 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, NDV-generated tumor oncolysates have been shown to be more effective stimulators of immune response than oncolysates generated by other methods37. Studies also indicate that the viral HN and F proteins modify the surface of the infected cells to allow for better lymphocyte adhesion38,39. In addition, viral infection stimulates the local production of cytokines and chemokines which enhance antitumor responses.…”

Section: Discussionmentioning

confidence: 99%

Genetically engineered Newcastle disease virus for malignant melanoma therapy

et al. 2009

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Genetically engineered Newcastle disease virus for malignant melanoma therapy

et al. 2009

View full text Add to dashboard Cite

“…Malignant cells overexpressing the IL-2R (for example, Burkitt's or other lymphoma cells) could be targeted by the recombinant NDV. Expressing the β-glucuronidase gene, the virus enables tumor cells to cleave cytotoxic drugs from prodrugs [139]. Melanoma cells transfected with the MHC gene and infected with NDV proved to be highly immunogenic vaccines [298].…”

Section: Naturally Oncolytic Viruses Genetically Engineered or Otherwmentioning

confidence: 99%

Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers

Sinkovics

Horváth

2008

Arch. Immunol. Ther. Exp.

View full text Add to dashboard Cite

Based on personal acquaintances and experience dating back to the early 1950s, the senior author reviews the history of viral therapy of cancer. He points out the difficulties encountered in the treatment of human cancers, as opposed by the highly successful viral therapy of experimentally maintained tumors in laboratory animals, especially that of ascites carcinomas in mice. A detailed account of viral therapy of human tumors with naturally oncolytic viruses follows, emphasizing the first clinical trials with viral oncolysates. The discrepancy between the high success rates, culminating in cures, in the treatment of tumors of laboratory animals, and the moderate results, such as stabilizations of disease, partial responses, very rare complete remissions, and frequent relapses with virally treated human tumors is recognized. The preclinical laboratory testing against established human tumor cell lines that were maintained in tissue cultures for decades, and against human tumors extricated from their natural habitat and grown in xenografts, may not yield valid results predictive of the viral therapy applied against human tumors growing in their natural environment, the human host. Since the recent discovery of the oncosuppressive efficacy of bacteriophages, the colon could be regarded as the battlefield, where incipient tumor cells and bacteriophages vie for dominance. The inner environment of the colon will be the teaching ground providing new knowledge on the value of the anti-tumor efficacy of phage-induced innate anti-tumor immune reactions. Genetically engineered oncolytic viruses are reviewed next. The molecular biology of viral oncolysis is explained in details. Elaborate efforts are presented to elucidate how gene product proteins of oncolytic viruses switch off the oncogenic cascades of cancer cells. The facts strongly support the conclusion that viral therapy of human cancers will remain in the front lines of modern cancer therapeutics. It may be a combination of naturally oncolytic viruses and wild-type viruses rendered oncolytic and harmless by genetic engineering, that will induce complete remissions of human tumors. It may be necessary to co-administer certain chemotherapeutic agents, advanced cancer vaccines, or even immune lymphocytes, and targeted therapeuticals, to ascertain, that remissions induced by the viral agents will remain complete and durable; will co-operate with anti-tumor host immune reactions, and eventually will result in cures of advanced metastatic human cancers.

show abstract

“…The virus seems to selectively infect the tumour cells that in turn modify the cell surface and stimulate the production of cytokines such as interferons or tumour necrosis factor, which consequently activates a broader antitumour response in vivo (Haas et al, 1998;Schirrmacher et al, 1999aSchirrmacher et al, ,b, 2000. It is also probable that a direct virus-induced cell lysis mechanism is involved (Lorence et al, 1994;Sinkovics & Horvath, 2000).…”

Section: Opportunities From Ndvmentioning

confidence: 99%

Newcastle disease virus: Macromolecules and opportunities

Yusoff¹,

Tan²

2001

Avian Pathology

141

111

View full text Add to dashboard Cite

Over the past two decades, enormous advances have occurred in the structural and biological characterization of Newcastle disease virus (NDV). As a result, not only the complete sequence of the viral genome has been fully determined, but also a clearer understanding of the viral proteins and their respective roles in the life cycle has been achieved. This article reviews the progress in the molecular biology of NDV with emphasis on the new technologies. It also identifies the fundamental problems that need to be addressed and attempts to predict some research opportunities in NDV that can be realized in the near future for the diagnosis, prevention and treatment of disease(s).

show abstract

Introduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle Disease Virus.

Cited by 26 publications

References 0 publications

Genetically engineered Newcastle disease virus for malignant melanoma therapy

Genetically engineered Newcastle disease virus for malignant melanoma therapy

Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers

Newcastle disease virus: Macromolecules and opportunities

Contact Info

Product

Resources

About